Xavier Kubiak1, Romain Duval2, Benjamin Pluvinage3, Alain F Chaffotte4, Jean-Marie Dupret2, Fernando Rodrigues-Lima2. 1. Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France. 2. Sorbonne Paris Cité, Univ Paris Diderot, Unité BFA, CNRS UMR 8251, Paris, France. 3. Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada. 4. Unité de Résonance Magnétique Nucléaire des Biomolécules, Institut Pasteur, Paris, France.
Abstract
BACKGROUND AND PURPOSE: The arylamine N-acetyltransferases (NATs) are xenobiotic-metabolizing enzymes that play an important role in the detoxification and/or bioactivation of arylamine drugs and xenobiotics. In bacteria, NATs may contribute to the resistance against antibiotics such as isoniazid or sulfamides through their acetylation, which makes this enzyme family a possible drug target. Bacillus anthracis, a bacterial species of clinical significance, expresses three NAT isozymes with distinct structural and enzymatic properties, including an inactive isozyme ((BACAN)NAT3). (BACAN)NAT3 features both a non-canonical Glu residue in its catalytic triad and a truncated C-terminus domain. However, the role these unusual characteristics play in the lack of activity of the (BACAN)NAT3 isozyme remains unclear. EXPERIMENTAL APPROACH: Protein engineering, recombinant expression, enzymatic analyses with aromatic amine substrates and phylogenetic analysis approaches were conducted. KEY RESULTS: The deletion of guanine 580 (G580) in the nat3 gene was shown to be responsible for the expression of a truncated (BACAN)NAT3 isozyme. Artificial re-introduction of G580 in the nat3 gene led to a functional enzyme able to acetylate several arylamine drugs displaying structural characteristics comparable with its functional Bacillus cereus homologue ((BACCR)NAT3). Phylogenetic analysis of the nat3 gene in the B. cereus group further indicated that nat3 may constitute a pseudogene of the B. anthracis species. CONCLUSION AND IMPLICATIONS: The existence of NATs with distinct properties and evolution in Bacillus species may account for their adaptation to their diverse chemical environments. A better understanding of these isozymes is of importance for their possible use as drug targets. LINKED ARTICLES: This article is part of a themed section on Drug Metabolism and Antibiotic Resistance in Micro-organisms. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.14/issuetoc.
BACKGROUND AND PURPOSE: The arylamine N-acetyltransferases (NATs) are xenobiotic-metabolizing enzymes that play an important role in the detoxification and/or bioactivation of arylamine drugs and xenobiotics. In bacteria, NATs may contribute to the resistance against antibiotics such as isoniazid or sulfamides through their acetylation, which makes this enzyme family a possible drug target. Bacillus anthracis, a bacterial species of clinical significance, expresses three NAT isozymes with distinct structural and enzymatic properties, including an inactive isozyme ((BACAN)NAT3). (BACAN)NAT3 features both a non-canonical Glu residue in its catalytic triad and a truncated C-terminus domain. However, the role these unusual characteristics play in the lack of activity of the (BACAN)NAT3 isozyme remains unclear. EXPERIMENTAL APPROACH: Protein engineering, recombinant expression, enzymatic analyses with aromatic amine substrates and phylogenetic analysis approaches were conducted. KEY RESULTS: The deletion of guanine 580 (G580) in the nat3 gene was shown to be responsible for the expression of a truncated (BACAN)NAT3 isozyme. Artificial re-introduction of G580 in the nat3 gene led to a functional enzyme able to acetylate several arylamine drugs displaying structural characteristics comparable with its functional Bacillus cereus homologue ((BACCR)NAT3). Phylogenetic analysis of the nat3 gene in the B. cereus group further indicated that nat3 may constitute a pseudogene of the B. anthracis species. CONCLUSION AND IMPLICATIONS: The existence of NATs with distinct properties and evolution in Bacillus species may account for their adaptation to their diverse chemical environments. A better understanding of these isozymes is of importance for their possible use as drug targets. LINKED ARTICLES: This article is part of a themed section on Drug Metabolism and Antibiotic Resistance in Micro-organisms. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.14/issuetoc.
Authors: Benjamin Pluvinage; Inés Li de la Sierra-Gallay; Xavier Kubiak; Ximing Xu; Julien Dairou; Jean-Marie Dupret; Fernando Rodrigues-Lima Journal: FEBS Lett Date: 2011-11-02 Impact factor: 4.124
Authors: Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath Journal: Br J Pharmacol Date: 2015-07 Impact factor: 8.739
Authors: Xavier Kubiak; Delphine Dervins-Ravault; Benjamin Pluvinage; Alain F Chaffotte; Laura Gomez-Valero; Julien Dairou; Florent Busi; Jean-Marie Dupret; Carmen Buchrieser; Fernando Rodrigues-Lima Journal: Biochem J Date: 2012-07-15 Impact factor: 3.857
Authors: Elizabeth Fullam; Isaac M Westwood; Matthew C Anderton; Edward D Lowe; Edith Sim; Martin E M Noble Journal: J Mol Biol Date: 2007-10-13 Impact factor: 5.469
Authors: Benjamin Pluvinage; Julien Dairou; Odile M Possot; Marta Martins; Agnès Fouet; Jean-Marie Dupret; Fernando Rodrigues-Lima Journal: Biochemistry Date: 2007-05-19 Impact factor: 3.162
Authors: Areej Abuhammad; Elizabeth Fullam; Edward D Lowe; David Staunton; Akane Kawamura; Isaac M Westwood; Sanjib Bhakta; Alun Christopher Garner; David L Wilson; Peter T Seden; Stephen G Davies; Angela J Russell; Elspeth F Garman; Edith Sim Journal: PLoS One Date: 2012-12-28 Impact factor: 3.240